Macular disease

Melbourne-based biotech company Opthea has announced it has secured commitments from both Australian and international investors for an additional $50...

Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of...

Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use...

Optometrists performing intravitreal injections is one of several key issues to be addressed by a newly formed Optometry Australia (OA)...

The University of Melbourne is recruiting optometrists to test new clinical tools, as well as an auditing system, it has...

Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the...

The Lions Eye Institute (LEI) has signed a commercial partnership that will combine its antisense gene therapy for a leading cause of...

Controversial plans to dramatically reduce the rebate for intravitreal injections and also allow non-ophthalmologists to perform the procedure have divided...

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate...

A significant Australian study into the effectiveness of Allergan’s Ozurdex implant as a treatment for Diabetic Macular Oedema (DME) has...